Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Enloe Medical Center — Chico, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Health System - Encinitas — Encinitas, California
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in California: - Alta Bates Summit Medical Center — Berkeley, California
- Community Cancer Institute — Clovis, California
- PIH Health Whittier Hospital — Downey, California
- Compassionate Cancer Care Medical Group - Inc — Fountain Valley, California
- Los Angeles Cancer Network — Los Angeles, California
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in California: - Comprehensive Blood & Cancer Center — Bakersfield, California
- UCSF Cancer Center Berkeley — Berkeley, California
- Cedars-Sinai Cancer Beverly Hills — Beverly Hills, California
- City of Hope National Medical Center — Duarte, California
- UCSF Wash Cancer CNTR — Fremont, California
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- Onco Inst of Hope and Innovation — Cerritos, California
- City of Hope National Medical — Duarte, California
- Providence Medical Foundation — Fullerton, California
- Los Angeles Cancer Network Good Samaritan — Los Angeles, California
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in California: - Research Site — Duarte, California
- Research Site — Fountain Valley, California
- Research Site — Glendale, California
- Research Site — Sacramento, California
- Research Site — Santa Rosa, California
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in California: - Sutter Auburn Faith Hospital — Auburn, California
- La Hematology Oncology Medical Group — Glendale, California
- Marin Cancer Care Inc — Greenbrae, California
- Kaiser Permanente - Harbor City — Harbor City, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in California: - Roy and Patricia Disney Family Cancer Center ( Site 0055) — Burbank, California
- Community Cancer Institute ( Site 0100) — Clovis, California
- Providence Medical Foundation ( Site 0080) — Fullerton, California
- MemorialCare Health System - Long Beach Medical Center ( Site 9556) — Long Beach, California
- El Camino Hospital Cancer Center ( Site 0096) — Mountain View, California
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in California: - Disney Family Cancer Center — Burbank, California
- City of Hope - Lennar Foundation Cancer Center — Irvine, California
- Scripps Health — La Jolla, California
- City Of Hope — Long Beach, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in California: - UC San Diego Health System - Encinitas — Encinitas, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- California Protons Cancer Therapy Center — San Diego, California
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in California: - City of Hope - Duarte Cancer Center — Duarte, California
- Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center — Fullerton, California
- City of Hope - Orange County Lennar Foundation Cancer Center — Irvine, California
- University of California San Diego - Moores Cancer Center — La Jolla, California
- University of Southern California - Norris Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in California: - The Oncology Institute Of Hope And Innovation — Cerritos, California
- Los Angeles Hematology Oncology Medical Group Glendale — Glendale, California
- USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS — Los Angeles, California
- UCSF at Mission Bay MB — San Francisco, California
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in California: - Providence Medical Foundation - Santa Rosa, CA — Santa Rosa, California
Phase 3 Recruiting Industry
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …
Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in California: - City of Hope Medical Center — Duarte, California
- Providence Medical Foundation — Fullerton, California
- UCLA Hematology Oncology Santa Monica — Los Angeles, California
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in California: - PCR Oncology — Arroyo Grande, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Epic Care-Dublin — Dublin, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- MemorialCare Orange Coast Medical Center — Fountain Valley, California
- City of Hope at Orange County Lennar Foundation Cancer Center — Irvine, California
- LA Cancer Network — Los Angeles, California
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in California: - Helios Clinical Research — Cerritos, California
- California Research Institute — Los Angeles, California
- Sharp Memorial Hospital — San Diego, California
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in California: - Oncology Institute — Long Beach, California
- Cancer & Blood Research Center — Los Alamitos, California
Phase 1, Phase 2 Recruiting Industry
A Study of Emi-Le in Participants with Solid Tumors
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05377996
Sites in California: - UC Irvine Health-Chao Family Comprehensive Cancer Center — Orange, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- UCLA David Geffen School of Medicine, Division of Hematology/Oncology — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in California: - The Oncology Institute of Hope and Innovation — Cerritos, California
- Ellison Medical Institute — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California Los Angeles — Los Angeles, California
- University of California Irvine — Orange, California
Phase 2 Recruiting Industry
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…
Sponsor: Pfizer
NCT ID: NCT04606446
Sites in California: - Cedars Sinai Medical Center — Los Angeles, California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
- UCSF Medical Center at Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven …
Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in California: - City of Hope — Duarte, California
- University of California San Diego (UCSD) - Koman Family Outpatient Pavilion ? La Jolla — La Jolla, California
- University of California San Diego Medical Center — La Jolla, California
- Stanford Cancer Institute — Stanford, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in California: - City of Hope — Duarte, California
- City of Hope — Huntington Beach, California
- City of Hope — Irvine, California
- City of Hope — Long Beach, California
- University of California, San Francisco — San Francisco, California